A Phase 3 interventional study of V116 and Placebo in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 44 sites in 8 countries. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 7th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 518 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 22nd largest by enrollment, is one of 2 that started in 2023, is one of 31 in phase 3, and was the 41st registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the safety and tolerability of the pneumococcal 21 valent conjugate vaccine (V116), and to evaluate the serotype-specific opsonophagocytic activity (OPA) post-vaccination with V116 and PCV15 (a pneumococcal conjugate vaccine that includes 15 serotypes) + PPSV23 (comprised of the polysaccharides from 23 of the serotypes causing disease in adults) post-vaccination within each vaccination group separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants administered a single intramuscular (IM) dose of V116 on Day 1, and single IM dose of placebo on Week 8.
Biological: V116 · Biological: Placebo
Participants administered a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
Biological: PCV15 · Biological: PPSV23
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Saline in each 0.5 mL sterile solution
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Also known as: VAXNEUVANCE™
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PNEUMOVAX™23
Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs was assessed following any vaccination. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.
Time frame: Up to 5 days following each vaccination
Participants With Solicited Systemic AEs From Day 1 Through Day 5 Post-vaccination
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature \>= 100.4 °F/38.0 °C).
Time frame: Up to 5 days following each vaccination
Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study
A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, which is determined by the investigator to be related to the vaccine. The percentage of participants with SAEs was assessed following any vaccination.
Time frame: Up to 194 days following Visit 2 (Day 1)
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Pneumococcal Serotypes Contained in V116
The serotype specific OPA GMTs for the pneumococcal serotypes were determined using the multiplex opsonophagocytic assay (MOPA). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: 30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Pneumococcal Serotypes Contained in V116
The serotype specific IgG GMCs for the pneumococcal serotypes were determined using pneumococcal electrochemiluminescence assay (PnECL). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: 30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group.
Serotype-specific Geometric Mean Fold Rises (GMFRs) for OPA Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23
The geometric mean fold rise (GMFR) from baseline to post-vaccination in serotype specific OPA GMTs was determined using MOPA. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Serotype-specific GMFRs for IgG Responses From Baseline to Post-vaccination With V116 and PCV15 + PPSV23
The GMFR from baseline to post-vaccination in serotype specific IgG GMCs was determined using Pn electrochemiluminescence (ECL) assay. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Percentage of Participants With ≥4-fold Change From Baseline to Post-vaccination With V116 and PCV15 + PPSV23 in Serotype Specific OPA Responses for Pneumococcal Serotypes Contained in V116
The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using MOPA. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Percentage of Participants With ≥4-fold Change From Baseline to Post-Vaccination With V116 and PCV15 + PPSV23 in Serotype Specific IgG Responses for Pneumococcal Serotypes Contained in V116
The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using Pn ECL assay. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
Time frame: Baseline (Day 1) and postvaccination (30 days following V116 [Day 30] for the V116 + Placebo group and 30 days following PPSV23 [Week 12] for the PCV15 + PPSV23 group)
Pneumococcal vaccine-naïve adults 18 to 64 years of age (inclusive) with increased risk of pneumococcal disease were enrolled in this study. Participants must have had documented results of ≥ 1 of the following risk conditions: diabetes mellitus, chronic heart disease, chronic kidney disease, chronic liver disease, and/or chronic lung disease. Participants with comorbidities were eligible if the conditions were assessed to be stable as per the investigator's judgment.
| Milestone | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Started | 387 | 131 |
| Vaccinated with v116 at visit 2 | 386 | 0 |
| Vaccinated with pcv15 at visit 2 | 0 | 130 |
| Vaccinated with placebo at visit 5 | 374 | 0 |
| Vaccinated with ppsv23 at visit 5 | 0 | 128 |
| Completed | 372 | 129 |
| Not completed | 15 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Randomized by mistake without study treatment | 0 | 1 |
| Withdrew: Withdrawal by subject | 12 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs was assessed following any vaccination. Solicited injection-site AEs consist of the following: pain/tenderness, redness/erythema, and swelling.
| Percentage of participants | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Injection site erythema | 9.1 (6.4 to 12.4) | 25.4 (18.2 to 33.8) |
| Injection site pain | 51.8 (46.7 to 56.9) | 78.5 (70.4 to 85.2) |
| Injection site swelling | 8.0 (5.5 to 11.2) | 35.4 (27.2 to 44.2) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature \>= 100.4 °F/38.0 °C).
| Percentage of participants | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Fatigue | 30.3 (25.8 to 35.2) | 45.4 (36.6 to 54.3) |
| Headache | 22.3 (18.2 to 26.8) | 26.2 (18.8 to 34.6) |
| Myalgia | 10.9 (8.0 to 14.4) | 15.4 (9.7 to 22.8) |
| Pyrexia | 3.1 (1.6 to 5.4) | 4.6 (1.7 to 9.8) |
A vaccine-related SAE is any untoward medical consequence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, which is determined by the investigator to be related to the vaccine. The percentage of participants with SAEs was assessed following any vaccination.
| Percentage of participants | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through The Duration of Participation in The Study | 0.0 (0.0 to 1.0) | 0.0 (0.0 to 2.8) |
The serotype specific OPA GMTs for the pneumococcal serotypes were determined using the multiplex opsonophagocytic assay (MOPA). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Titers | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Serotype 3 | 216.2 (188.6 to 247.8) | 192.9 (156.7 to 237.4) |
| Serotype 6A | 3734.9 (3204.3 to 4353.4) | 2443.8 (1779.0 to 3357.1) |
| Serotype 7F | 4261.2 (3781.6 to 4801.6) | 3218.5 (2627.3 to 3942.6) |
| Serotype 8 | 3460.8 (3083.1 to 3884.7) | 3406.4 (2635.8 to 4402.2) |
| Serotype 9N | 7553.9 (6664.1 to 8562.5) | 4548.4 (3696.8 to 5596.2) |
| Serotype 10A | 4502.0 (3933.7 to 5152.4) | 2542.0 (1897.0 to 3406.2) |
| Serotype 11A | 3761.7 (3375.8 to 4191.7) | 1697.2 (1338.4 to 2152.2) |
| Serotype 12F | 2432.3 (2082.7 to 2840.6) | 1364.5 (956.1 to 1947.4) |
| Serotype 17F | 10425.3 (9099.2 to 11944.7) | 4331.7 (3248.3 to 5776.3) |
| Serotype 19A | 2837.2 (2535.2 to 3175.2) | 2437.2 (2008.5 to 2957.5) |
| Serotype 20A | 8091.5 (7169.4 to 9132.3) | 3749.8 (2932.4 to 4795.2) |
| Serotype 22F | 4432.7 (3914.2 to 5020.0) | 2717.4 (2201.7 to 3353.8) |
| Serotype 33F | 24512.8 (21149.8 to 28410.7) | 11395.1 (8884.5 to 14615.3) |
| Serotype 15A | 7274.6 (6398.7 to 8270.4) | 1791.8 (1361.7 to 2357.8) |
| Serotype 15C | 7923.1 (6726.7 to 9332.3) | 2269.8 (1651.8 to 3118.9) |
| Serotype 16F | 9546.6 (8396.2 to 10854.6) | 1626.2 (1224.4 to 2159.8) |
| Serotype 23A | 5875.3 (5005.5 to 6896.2) | 1493.9 (1009.1 to 2211.5) |
| Serotype 23B | 2316.9 (1925.9 to 2787.3) | 117.0 (73.4 to 186.4) |
| Serotype 24F | 5677.1 (5098.2 to 6321.8) | 1666.8 (1257.6 to 2209.1) |
| Serotype 31 | 5803.9 (4991.8 to 6748.1) | 360.7 (233.0 to 558.5) |
| Serotype 35B | 13141.3 (11584.8 to 14906.9) | 1812.1 (1408.6 to 2331.2) |
The serotype specific IgG GMCs for the pneumococcal serotypes were determined using pneumococcal electrochemiluminescence assay (PnECL). The point estimate was calculated by exponentiating the estimates of the mean of the natural log values and within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| μg/mL | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Serotype 3 | 0.77 (0.69 to 0.87) | 0.79 (0.68 to 0.92) |
| Serotype 6A | 4.57 (3.82 to 5.48) | 5.83 (4.23 to 8.03) |
| Serotype 7F | 8.77 (7.65 to 10.06) | 6.95 (5.39 to 8.96) |
| Serotype 8 | 10.20 (8.89 to 11.71) | 12.50 (9.68 to 16.14) |
| Serotype 9N | 7.53 (6.42 to 8.83) | 4.35 (3.35 to 5.66) |
| Serotype 10A | 12.18 (10.36 to 14.32) | 6.88 (5.07 to 9.34) |
| Serotype 11A | 7.78 (6.80 to 8.89) | 4.04 (3.22 to 5.07) |
| Serotype 12F | 1.90 (1.58 to 2.28) | 0.84 (0.60 to 1.18) |
| Serotype 17F | 17.35 (15.06 to 19.98) | 8.20 (6.32 to 10.64) |
| Serotype 19A | 9.11 (7.98 to 10.41) | 10.88 (8.70 to 13.60) |
| Serotype 20A | 19.51 (16.73 to 22.75) | 13.38 (10.27 to 17.43) |
| Serotype 22F | 5.17 (4.44 to 6.02) | 3.98 (3.08 to 5.14) |
| Serotype 33F | 15.38 (13.23 to 17.88) | 11.40 (8.99 to 14.46) |
| Serotype 15A | 14.65 (12.52 to 17.13) | 2.37 (1.77 to 3.18) |
| Serotype 15C | 14.48 (12.07 to 17.38) | 5.42 (3.98 to 7.37) |
| Serotype 16F | 2.90 (2.48 to 3.38) | 0.27 (0.21 to 0.35) |
| Serotype 23A | 3.85 (3.18 to 4.66) | 0.79 (0.56 to 1.11) |
| Serotype 23B | 6.62 (5.75 to 7.63) | 1.46 (1.09 to 1.96) |
| Serotype 24F | 5.18 (4.17 to 6.43) | 0.34 (0.26 to 0.43) |
| Serotype 31 | 3.27 (2.83 to 3.79) | 0.38 (0.29 to 0.49) |
| Serotype 35B | 19.78 (17.38 to 22.50) | 1.55 (1.27 to 1.90) |
The geometric mean fold rise (GMFR) from baseline to post-vaccination in serotype specific OPA GMTs was determined using MOPA. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Ratio | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Serotype 3 | 8.3 (7.2 to 9.5) | 6.1 (4.8 to 7.7) |
| Serotype 6A | 22.8 (18.6 to 28.0) | 17.1 (11.9 to 24.7) |
| Serotype 7F | 20.4 (16.9 to 24.6) | 10.5 (7.5 to 14.7) |
| Serotype 8 | 25.7 (21.1 to 31.2) | 25.2 (17.0 to 37.1) |
| Serotype 9N | 12.6 (10.6 to 15.0) | 7.2 (5.5 to 9.5) |
| Serotype 10A | 19.9 (16.1 to 24.5) | 10.7 (7.2 to 15.8) |
| Serotype 11A | 20.7 (16.6 to 25.8) | 6.8 (4.6 to 10.1) |
| Serotype 12F | 95.0 (79.9 to 113.0) | 48.6 (32.5 to 72.6) |
| Serotype 17F | 28.4 (23.6 to 34.2) | 13.1 (9.5 to 18.1) |
| Serotype 19A | 9.7 (8.2 to 11.5) | 9.9 (7.2 to 13.6) |
| Serotype 20A | 8.5 (7.2 to 10.0) | 3.8 (3.0 to 5.0) |
| Serotype 22F | 15.1 (12.2 to 18.7) | 9.1 (6.0 to 13.7) |
| Serotype 33F | 12.3 (10.4 to 14.5) | 5.5 (4.1 to 7.2) |
| Serotype 15A | 10.4 (8.6 to 12.5) | 2.4 (1.8 to 3.2) |
| Serotype 15C | 52.8 (42.1 to 66.2) | 18.3 (12.2 to 27.4) |
| Serotype 16F | 8.6 (7.3 to 10.1) | 1.6 (1.2 to 2.0) |
| Serotype 23A | 14.5 (11.4 to 18.6) | 4.3 (2.7 to 6.8) |
| Serotype 23B | 83.6 (66.4 to 105.3) | 6.2 (4.3 to 9.0) |
| Serotype 24F | 4.0 (3.4 to 4.7) | 0.9 (0.7 to 1.2) |
| Serotype 31 | 23.2 (18.4 to 29.1) | 1.5 (1.2 to 2.0) |
| Serotype 35B | 7.2 (6.3 to 8.3) | 1.2 (1.0 to 1.4) |
The GMFR from baseline to post-vaccination in serotype specific IgG GMCs was determined using Pn electrochemiluminescence (ECL) assay. The within-group 95% confidence intervals (Cis) were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Ratio | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Serotype 3 | 5.2 (4.7 to 5.8) | 4.5 (3.8 to 5.4) |
| Serotype 6A | 16.2 (13.9 to 18.9) | 20.1 (15.5 to 26.0) |
| Serotype 7F | 19.0 (16.8 to 21.5) | 12.8 (10.2 to 16.2) |
| Serotype 8 | 14.8 (12.9 to 17.0) | 15.5 (11.5 to 21.0) |
| Serotype 9N | 19.2 (16.8 to 22.0) | 9.9 (7.9 to 12.5) |
| Serotype 10A | 20.1 (17.6 to 23.0) | 11.0 (8.6 to 13.9) |
| Serotype 11A | 11.7 (10.3 to 13.3) | 5.6 (4.5 to 7.0) |
| Serotype 12F | 17.7 (15.3 to 20.5) | 8.1 (6.2 to 10.6) |
| Serotype 17F | 29.6 (25.9 to 33.8) | 13.9 (10.9 to 17.6) |
| Serotype 19A | 7.1 (6.3 to 8.0) | 8.1 (6.5 to 10.0) |
| Serotype 20A | 15.1 (13.2 to 17.2) | 8.7 (7.0 to 10.8) |
| Serotype 22F | 19.7 (17.0 to 22.8) | 13.2 (10.2 to 17.3) |
| Serotype 33F | 14.7 (13.0 to 16.6) | 11.0 (8.8 to 13.8) |
| Serotype 15A | 23.6 (20.6 to 27.1) | 3.7 (3.0 to 4.6) |
| Serotype 15C | 24.2 (20.8 to 28.2) | 9.2 (7.3 to 11.7) |
| Serotype 16F | 16.0 (14.1 to 18.1) | 1.6 (1.4 to 1.9) |
| Serotype 23A | 20.9 (18.2 to 24.0) | 3.8 (2.9 to 4.9) |
| Serotype 23B | 16.6 (14.3 to 19.2) | 3.7 (3.0 to 4.6) |
| Serotype 24F | 18.0 (15.5 to 20.9) | 1.1 (1.1 to 1.2) |
| Serotype 31 | 14.4 (12.7 to 16.4) | 1.5 (1.4 to 1.7) |
| Serotype 35B | 12.8 (11.3 to 14.5) | 1.0 (1.0 to 1.1) |
The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using MOPA. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Percentage of Participants | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Serotype 3 | 70.1 (64.8 to 74.9) | 63.7 (53.6 to 73.0) |
| Serotype 6A | 79.1 (74.1 to 83.6) | 79.3 (68.9 to 87.4) |
| Serotype 7F | 78.3 (73.5 to 82.6) | 63.6 (53.7 to 72.6) |
| Serotype 8 | 84.6 (80.3 to 88.2) | 82.5 (73.8 to 89.3) |
| Serotype 9N | 74.7 (69.7 to 79.3) | 58.9 (49.0 to 68.3) |
| Serotype 10A | 74.9 (69.9 to 79.5) | 70.4 (60.3 to 79.2) |
| Serotype 11A | 76.7 (71.7 to 81.2) | 49.0 (38.9 to 59.2) |
| Serotype 12F | 94.2 (91.1 to 96.4) | 85.0 (76.9 to 91.2) |
| Serotype 17F | 89.6 (85.8 to 92.7) | 76.2 (66.7 to 84.1) |
| Serotype 19A | 68.0 (62.7 to 72.9) | 68.6 (58.7 to 77.5) |
| Serotype 20A | 66.9 (61.5 to 71.9) | 42.3 (32.3 to 52.7) |
| Serotype 22F | 74.8 (69.7 to 79.5) | 57.8 (47.7 to 67.6) |
| Serotype 33F | 78.5 (73.7 to 82.8) | 58.0 (47.7 to 67.8) |
| Serotype 15A | 67.6 (62.1 to 72.8) | 29.5 (20.6 to 39.7) |
| Serotype 15C | 86.0 (81.8 to 89.5) | 72.4 (62.8 to 80.7) |
| Serotype 16F | 65.6 (60.2 to 70.7) | 16.7 (9.8 to 25.6) |
| Serotype 23A | 71.3 (65.4 to 76.7) | 52.6 (40.8 to 64.2) |
| Serotype 23B | 87.7 (83.7 to 91.0) | 49.1 (39.2 to 59.0) |
| Serotype 24F | 41.6 (35.9 to 47.5) | 6.2 (2.0 to 13.8) |
| Serotype 31 | 77.0 (72.2 to 81.4) | 16.2 (9.5 to 24.9) |
| Serotype 35B | 64.4 (59.0 to 69.5) | 5.9 (2.2 to 12.4) |
The percentage of participants with ≥4-fold rise from baseline to post-vaccination with V116 and PCV15+PPSV23 in serotype-specific OPA responses for pneumococcal serotypes contained in V116 was calculated using Pn ECL assay. The 13 common pneumococcal serotypes in both V116 and PCV15 + PPSV23 were as follows: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 17F, 19A, 20A, 22F, and 33F. The 8 unique pneumococcal serotypes in V116 were as follows: 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B.
| Percentage of Participants | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Serotype 3 | 57.8 (52.6 to 62.9) | 54.1 (44.3 to 63.6) |
| Serotype 6A | 81.1 (76.8 to 85.0) | 86.5 (78.7 to 92.2) |
| Serotype 7F | 88.8 (85.1 to 91.8) | 83.8 (75.6 to 90.1) |
| Serotype 8 | 82.2 (77.9 to 86.0) | 83.8 (75.6 to 90.1) |
| Serotype 9N | 86.9 (83.0 to 90.2) | 78.4 (69.6 to 85.6) |
| Serotype 10A | 86.3 (82.4 to 89.7) | 79.3 (70.5 to 86.4) |
| Serotype 11A | 79.8 (75.3 to 83.8) | 63.1 (53.4 to 72.0) |
| Serotype 12F | 82.8 (78.5 to 86.5) | 69.4 (59.9 to 77.8) |
| Serotype 17F | 93.2 (90.1 to 95.5) | 82.9 (74.6 to 89.4) |
| Serotype 19A | 64.2 (59.1 to 69.1) | 73.0 (63.7 to 81.0) |
| Serotype 20A | 83.1 (78.8 to 86.8) | 75.7 (66.6 to 83.3) |
| Serotype 22F | 85.0 (80.9 to 88.5) | 83.8 (75.6 to 90.1) |
| Serotype 33F | 87.2 (83.3 to 90.4) | 79.3 (70.5 to 86.4) |
| Serotype 15A | 88.3 (84.5 to 91.4) | 44.1 (34.7 to 53.9) |
| Serotype 15C | 88.5 (84.8 to 91.6) | 75.5 (66.3 to 83.2) |
| Serotype 16F | 85.8 (81.8 to 89.2) | 7.3 (3.2 to 13.8) |
| Serotype 23A | 88.3 (84.5 to 91.4) | 37.8 (28.8 to 47.5) |
| Serotype 23B | 81.7 (77.3 to 85.5) | 43.2 (33.9 to 53.0) |
| Serotype 24F | 82.0 (77.6 to 85.8) | 2.7 (0.6 to 7.7) |
| Serotype 31 | 83.1 (78.8 to 86.8) | 9.9 (5.1 to 17.0) |
| Serotype 35B | 79.5 (75.0 to 83.5) | 0.9 (0.0 to 4.9) |
Collected over Up to ~ 194 Days following Visit 2 (Day 1). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V116 + Placebo | 0/387 (0%) | 10/386 (2.6%) | 240/386 (62.2%) |
| PCV15 + PPSV23 | 0/131 (0%) | 7/130 (5.4%) | 112/130 (86.2%) |
| Event | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Coronary artery stenosisCardiac disorders | 0/386 | 1/130 |
| Ventricular tachycardiaCardiac disorders | 0/386 | 1/130 |
| Pancreatitis acuteGastrointestinal disorders | 0/386 | 1/130 |
| Pneumonia bacterialInfections and infestations | 0/386 | 1/130 |
| SeizureNervous system disorders | 0/386 | 1/130 |
| SyncopeNervous system disorders | 0/386 | 1/130 |
| Acute kidney injuryRenal and urinary disorders | 0/386 | 1/130 |
| Deep vein thrombosisVascular disorders | 0/386 | 1/130 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/386 | 0/130 |
| Obstructive pancreatitisGastrointestinal disorders | 1/386 | 0/130 |
| Event | V116 + Placebo | PCV15 + PPSV23 |
|---|---|---|
| Injection site painGeneral disorders | 200/386 | 102/130 |
| FatigueGeneral disorders | 118/386 | 59/130 |
| Injection site swellingGeneral disorders | 33/386 | 46/130 |
| HeadacheNervous system disorders | 94/386 | 36/130 |
| Injection site erythemaGeneral disorders | 39/386 | 33/130 |
| MyalgiaMusculoskeletal and connective tissue disorders | 42/386 | 20/130 |
| Age, Continuous(Years) | V116 + Placebo | PCV15 + PPSV23 | Total |
|---|---|---|---|
| Mean | 52.4 ± 9.6 | 53.3 ± 8.9 | 52.6 ± 9.4 |
| Sex: Female, Male(Participants) | V116 + Placebo | PCV15 + PPSV23 | Total |
|---|---|---|---|
| Female | 178 | 55 | 233 |
| Male | 209 | 76 | 285 |
| Ethnicity (NIH/OMB)(Participants) | V116 + Placebo | PCV15 + PPSV23 | Total |
|---|---|---|---|
| Hispanic or Latino | 101 | 35 | 136 |
| Not Hispanic or Latino | 281 | 94 | 375 |
| Unknown or Not Reported | 5 | 2 | 7 |
| Race (NIH/OMB)(Participants) | V116 + Placebo | PCV15 + PPSV23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 58 | 18 | 76 |
| Native Hawaiian or Other Pacific Islander | 10 | 8 | 18 |
| Black or African American | 16 | 2 | 18 |
| White | 294 | 101 | 395 |
| More than one race | 8 | 2 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2023 to primary completion in Feb 2024, 12 months.
Results were first posted in Feb 2025, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine